Loading…

Protection of melatonin in experimental models of newborn hypoxic‐ischemic brain injury through MT1 receptor

The function of melatonin as a protective agent against newborn hypoxic‐ischemic (H‐I) brain injury is not yet well studied, and the mechanisms by which melatonin causes neuroprotection in neurological diseases are still evolving. This study was designed to investigate whether expression of MT1 rece...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pineal research 2018-01, Vol.64 (1), p.n/a
Main Authors: Sinha, Bharati, Wu, Qiaofeng, Li, Wei, Tu, Yanyang, Sirianni, Ana C., Chen, Yanchun, Jiang, Jiying, Zhang, Xinmu, Chen, Wu, Zhou, Shuanhu, Reiter, Russel J., Manning, Simon M., Patel, Nirav J., Aziz‐Sultan, Ali M., Inder, Terrie E., Friedlander, Robert M., Fu, Jianfang, Wang, Xin
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The function of melatonin as a protective agent against newborn hypoxic‐ischemic (H‐I) brain injury is not yet well studied, and the mechanisms by which melatonin causes neuroprotection in neurological diseases are still evolving. This study was designed to investigate whether expression of MT1 receptors is reduced in newborn H‐I brain injury and whether the protective action of melatonin is by alterations of the MT1 receptors. We demonstrated that there was significant reduction in MT1 receptors in ischemic brain of mouse pups in vivo following H‐I brain injury and that melatonin offers neuroprotection through upregulation of MT1 receptors. The role of MT1 receptors was further supported by observation of increased mortality in MT1 knockout mice following H‐I brain injury and the reversal of the inhibitory role of melatonin on mitochondrial cell death pathways by the melatonin receptor antagonist, luzindole. These data demonstrate that melatonin mediates its neuroprotective effect in mouse models of newborn H‐I brain injury, at least in part, by the restoration of MT1 receptors, the inhibition of mitochondrial cell death pathways and the suppression of astrocytic and microglial activation.
ISSN:0742-3098
1600-079X
DOI:10.1111/jpi.12443